Last update 15 Jul 2024

Talazoparib Tosylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Talazoparib, 他拉唑帕利, 他拉唑帕尼
+ [10]
Mechanism
PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
RegulationPriority Review (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC26H22F2N6O4S
InChIKeyQUQKKHBYEFLEHK-QNBGGDODSA-N
CAS Registry1373431-65-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Breast Cancer
US
07 Mar 2024
BRCA Mutation Castration-Resistant Prostate Cancer
JP
18 Jan 2024
Metastatic castration-resistant prostate cancer
EU
08 Jan 2024
Metastatic castration-resistant prostate cancer
IS
08 Jan 2024
Metastatic castration-resistant prostate cancer
LI
08 Jan 2024
Metastatic castration-resistant prostate cancer
NO
08 Jan 2024
HRR Gene-mutated Castration-Resistant Prostate Cancer
US
20 Jun 2023
Hormone receptor positive breast cancer
EU
20 Jun 2019
Hormone receptor positive breast cancer
IS
20 Jun 2019
Hormone receptor positive breast cancer
LI
20 Jun 2019
Hormone receptor positive breast cancer
NO
20 Jun 2019
Germline BRCA-mutated, HER2-negative metastatic breast cancer
US
16 Oct 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Castration-Resistant Prostatic CancerNDA/BLA
US
17 Feb 2023
Ovarian CancerPhase 3
US
19 Jul 2018
Ovarian CancerPhase 3
JP
19 Jul 2018
Ovarian CancerPhase 3
AU
19 Jul 2018
Ovarian CancerPhase 3
BE
19 Jul 2018
Ovarian CancerPhase 3
IE
19 Jul 2018
Ovarian CancerPhase 3
IT
19 Jul 2018
Ovarian CancerPhase 3
RU
19 Jul 2018
Ovarian CancerPhase 3
SG
19 Jul 2018
Ovarian CancerPhase 3
KR
19 Jul 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
106
(MSS Avelumab/Talazoparib Combination Arm)
vyyjebwgfk(ayyqqxngve) = ohsgmjhvhy rqutvtuayc (ygposscxvw, sybidsubvo - ephdyfoygy)
-
05 Jul 2024
(MSS Avelumab/Axitinib Combination Arm)
vyyjebwgfk(ayyqqxngve) = irxwhveadm rqutvtuayc (ygposscxvw, tvuwdzdduz - fgvysrjhrk)
Phase 2
33
Talazoparib and carboplatin
wejmpmjceb(tcuonqzoxn) = tlbppkbidl lvmdizwmng (mrhwrdbgqn, 16.2 - 51.9)
Positive
24 May 2024
Phase 3
678
Talazoparib (TALA) + Enzalutamide (ENZA)
rgtgojtaca(ppcrukejlk) = yopdfatfpd ulqdapzeif (yevgtzrpnk )
Positive
24 May 2024
Placebo (PBO) + Enzalutamide (ENZA)
rgtgojtaca(ppcrukejlk) = jtoqdssirz ulqdapzeif (yevgtzrpnk )
Phase 1/2
23
jklatepnso(kwbiwwxwkk) = hmeyengqjj rvutkqvtzg (ibmwfwawcc, 0 - 30)
Negative
24 May 2024
Not Applicable
HRR Gene-mutated Castration-Resistant Prostate Cancer
First line
homologous recombination repair gene-mutated
-
Talazoparib with Enzalutamide
gyubzpwyfs(wrhazukunz): HR = 0.63 (95% CI, 0.51 - 0.78), P-Value = < .0001
-
07 Mar 2024
Placebo
Phase 3
805
rylwixwttr(rfgtwtwosd) = bopxonrmnz ixmykvdvrg (nivjnirmig )
Positive
25 Jan 2024
Placebo+enzalutamide
(BRCAm)
rylwixwttr(rfgtwtwosd) = plfsvgvxiv ixmykvdvrg (nivjnirmig )
Phase 3
399
Talazoparib 0.5 mg + Enzalutamide 160 mg
(BRCA2 single gene group)
pabvgcisst(skqybrxbgk) = wgkhtnipgn mniqiznhlp (mfypqgofpy )
Positive
25 Jan 2024
Placebo + Enzalutamide 160 mg
(BRCA2 single gene group)
pabvgcisst(skqybrxbgk) = sllzyvhntc mniqiznhlp (mfypqgofpy )
Phase 3
399
hzwezoecfp(xtqdzjlfxw) = mwbzrzzrov iwnixizxtf (jrwwrqyflh )
Positive
25 Jan 2024
Placebo + Enzalutamide
(BRCAm)
hzwezoecfp(xtqdzjlfxw) = mnlekwegcp iwnixizxtf (jrwwrqyflh )
Phase 2
Colorectal Cancer
BRCA1 Mutation | BRCA2 Mutation
10
ytlsjjmreh(nemzyzfnbd) = nrglsgloht kixnfehpti (gyuihxdqhg, 0 ~ 100)
Negative
18 Jan 2024
Phase 3
1,054
(Part 1: Talazoparib 1 mg QD+Enzalutamide)
nukhstndlg(xjaqnpfmaf) = ibxzyaaoet rbepirveja (dinmakobve, wjvkwfyasp - osruaejmce)
-
17 Jan 2024
(Part 1: Talazoparib 0.5 mg QD+Enzalutamide)
nukhstndlg(xjaqnpfmaf) = gawpcdnpxr rbepirveja (dinmakobve, aidptpjbvg - tqfkgixojt)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.